# A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

> **NCT03811561** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 1500 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT03811561
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-08
- **Primary completion:** 2027-11-07
- **Final completion:** 2027-11-07
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811561, "A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03811561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*